n-Hexane Quickview (CASRN 110-54-3)

Status of Data for n-Hexane

File First On-Line: 07/01/1990; Last Significant Revision: 12/23/2005

Category (section)	Status	Last Revised
Oral RfD Assessment	Discussion	12/23/2005
Inhalation RfC Assessment	On-line	12/23/2005
Carcinogenicity Assessment	Discussion	12/23/2005

Synonyms

110-54-3 n-Hexane Hexyl hydride

NCI-C60571 Skellysolve B

Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Not Assessed under the IRIS Program.

Top of page

---

Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect	Point of Departure*	UF	MF	RfC
Peripheral neuropathy (decreased MCV at 12 weeks)	BMCL (HEC): 215 mg/m3	300	1	7x10-1 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Inhalation RfC)
  • Rat subchronic inhalation study, Huang et al., 1989
• Confidence in the Inhalation RfC
  • Study -- Medium
  • Database -- Medium
  • RfC -- Medium

Top of page

Carcinogenicity Assessment for Lifetime Exposure

• Weight-of-Evidence Characterization
  • Inadequate information to assess carcinogenic potential
• Weight-of-Evidence Narrative:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005b), there is inadequate information to assess the carcinogenic potential of n-hexane.
  • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

---

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

• Not Assessed under the IRIS Program.

---

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

• Not Assessed under the IRIS Program.